The expression of sialic fibronectin correlates with lymph node metastasis of thyroid malignant neoplasmas

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1395-1398

  Takeyama, Hiroshi ^a,b   Kyoda, Shigeya ^a   Okamoto, Tomoyoshi ^a   Manome, Yoshinobu ^b   Watanabe, Michiko ^b   Kinoshita, Satoki ^b   Uchida, Ken ^b   Sakamoto, Atsuhiko ^c   Morikawa, Toshiaki ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lymph node metastasis; MoAb Jt 95; Sialic fibronectin; Thyroid malignant neoplasma

Indexed keywords

ANTIGEN; FIBRONECTIN; SIALIC ACID; SIALIC FIBRONECTIN ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASPIRATION BIOPSY; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADULT; ANTIBODIES, MONOCLONAL; CARCINOMA, PAPILLARY; FEMALE; FIBRONECTINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; PROGNOSIS; THYROID NEOPLASMS; YOUNG ADULT;

EID: 79956130402     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chen H, Nicol TL and Udelsman R: Follicular lesions of the thyroid. Does frozen section evaluation alter operative management? Ann Surg 222: 101-106, 1995.
2. McHenry CR, Thomas SR, Slusarczyk SJ and Khiyami A: Follicular or Hurthle cell neoplasm of the thyroid: Can clinical factors be used to predict carcinoma and determine extent of thyroidectomy? Surgery 126: 798-802, 1999.
3. Greaves TS, Olvera M, Florentine BD, Raza AS, Cobb CJ, Tsao-Wei DD, Groshen S, Singer P, Lopresti J and Martin SE: Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer 90: 335-334, 2000.
4. Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med 338: 297-306, 1998.
5. Follicular Chang HY, Lin JD, Chou SC, Chao TC and Hsueh C: Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas. Jpn J Clin Oncol 36: 688-693, 2006.
6. Young RL, Mazzaferri EL, Rahe AJ and Dorfman SG: Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nucl Med 21: 733-737, 1980 (Pubitemid 10037036)
7. Takano T, Matsuzuka F, Sumizaki H, Kuma K and Amino N: Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Res 57: 3792-3797, 1997. (Pubitemid 27381225)
8. Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P, Fontanini G, Ugolini C, Camacci T, De Ieso K, Miccoli P, Pinchera A and Basolo F: Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 13: 765-770, 2003. (Pubitemid 37070157)
9. Hesse E, Musholt PB, Potter E, Petrich T, Wehmeier M, von Wasielewski R, Lichtinghagen R and Musholt TJ: Oncofoetal fibronectin - a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma. Br J Cancer 93: 565-570, 2005. (Pubitemid 43080000)
10. Takeyama H, Hosoya T, Sakurai K, Mori Y, Watanabe M, Kisaki H and Ohno T: Production of a novel monoclonal antibody, JT-95, which can detect antigen of thyroid carcinoma. Cancer Res 56: 1817-1822, 1996.
11. Kimura N, Kurokawa K, Yamamoto K, Narimatsu H, Kimura H, Hosoya T and Takeyama H: Molecular identification of the antigens recognized by monoclonal antibody JT-95 specific for myroid carcinomas. Biochem Biophys Res Commun 251: 449-453, 1998. (Pubitemid 28505043)
12. Ryu S, Jimi S and Takebayashi S: Thyroid carcinoma distinctly express intracellular fibronectin in vivo. Cancer Lett 121: 189-193, 1997.
13. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A and Kloos RT: Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18: 48-57, 2005. (Pubitemid 40128094)
14. Matsuura H, Takio K, Titani K, Greene T, Levery SB, Salyan ME and Hakomori S: The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. Biol Chem 263: 3314-3322, 1988.
15. Loridon-Rosa B, Vielh P, Matsuura H, Clausen H, Cuadrado C and Burtin P: Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections. Cancer Res 50: 1608-1612, 1990. (Pubitemid 20090480)
16. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006. (Pubitemid 43278296)
17. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H and Taya Y: Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 68: 5104-5112, 2008.
18. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL and Weaver VM: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139: 891-906, 2009.
19. Hemler ME: VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 8: 365-400, 1990.
20. Guan JL and Hynes RO: Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell 60: 53-61, 1990.